Of two studies in ERCC4 rs1799801 (T>C, Ser835Ser) (Song et al., 2017; Zheng et al., 2017), one study in 437 NSCLC patients demonstrated an association of the ERCC4 rs1799801 with grade 3-4 hematologic toxicity in additive model (OR = 1.555; 95% CI: 1.041–2.323; p = 0.031) and grade 3-4 thrombocytopenia in dominant model (OR = 3.562; 95% CI: 1.513–8.390; p = 0.004) (Zheng et al., 2017). Here, ERCC4 is linked to non-small cell lung carcinoma.